Although SGLT2 inhibitors have shown an impressive positive effect on reducing composite major adverse cardiovascular events13, previous meta-analyses demonstrated that the effect of treatment with SGLT2 inhibitors was neutral on stroke outcome14. This evidence concerns the gene SLC5A2 and Stroke.